Program
palacaparib
Also written as “Palacaparib (AZD9574)”, “AZD8205 in combination with AZD9574” and “AZD9574”.
Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms, led by AstraZeneca.
Furthest: phase 2, since Oct 13, 20213 company-led studies, 3 open or runningNext primary completion: Sep 29, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 33 open or running | phase 2since Oct 13, 2021 | Oct 13, 2021 | Sep 29, 2027phase 2 · NCT05123482 |
- Named in AstraZeneca’s own pipeline as
AZD9574
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2021First study: phase 2 study in Breast NeoplasmsFirst studyNCT05123482 · 460 planned · United States, Australia, Belgium and more
- May 20, 2022Phase 2 study in Breast NeoplasmsNCT05417594 · 695 planned · United States, Australia, Germany and more
- May 11, 2026Phase 2 study in Prostatic NeoplasmsNCT07590934 · 152 planned · United States, Australia, Germany and more
Ahead
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
- Feb 7, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT05417594
- Sep 25, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07590934
TargetBeta
“An orally bioavailable central nervous system (CNS) penetrant and inhibitor of nuclear enzyme poly(ADP-ribose) polymerase (PARP) 1, with potential antineoplastic activity. Upon oral administration, palacaparib selectively binds to PARP1, thereby preventing repair of damaged DNA via the base excis…”NCIt, read by Claude
Other programs on PARP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olaparibrule | AstraZeneca | phase 4 | 78 |
| niraparibrule | GlaxoSmithKline | phase 4 | 43 |
| saruparibrule | AstraZeneca | phase 3 | 14 |
| senaparibrule | impact-therapeutics-inc | phase 2 | 12 |
| nesuparibrule | Jeil Pharmaceutical | phase 2 | 4 |
| PARP1 Inhibitor HS-10502rule | Hansoh Pharmaceutical Group | phase 1 | 2 |
| DM5167rule | digmbio | phase 1 | 1 |
| HSK46256rule | Haisco Pharmaceutical Group | phase 1 | 1 |
| TQB3122 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07590934Prostatic Neoplasms · United States, Australia, Germany and more | 2 | Recruiting | Sep 25, 2029 | 152 |
| NCT05417594Breast Neoplasms · United States, Australia, Germany and more | 2 | Recruiting | Feb 7, 2028 | 695 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 29, 2027 | 460 |
How it is read
Names in the registry
- “Palacaparib (AZD9574)”, 1 entry
- “AZD8205 in combination with AZD9574”, 1 entry
- “AZD9574”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.